Table 3.
Access to kidney replacement therapy
| 2016 (n = 63) | 2017 (n = 101) | 2018 (n = 103) | p-value | Total (%, 95 % CI) (n = 267) | p-value | |
|---|---|---|---|---|---|---|
| ESKD incidence rate, pmp (95 % CI) | 26.7 (20.0–33.4) | 41.4 (33.2–49.6) | 41.6 (33.4–49.8) |
0.006a 0.005b |
110.1 (96.6–123.6) | |
| Accepted for dialysis, n (%) | 19/63 (30.2 %; 20.0–42.8 %) | 28/101 (27.7 %; 19.8–37.3 %)) | 35/103 (34.0 %; 25.4–43.7 %)) | 0.622 | 82/267 (30.7 %; 25.4–36.5 %)) | |
| KRT incidence, pmp (95 % CI) | 8.05 (4.98–11.1) | 11.5 (7.83–15.1) | 14.1 (10.3–18.0) |
0.230a 0.045b |
33.8 (27.7–39.9) | |
| Age (years), median (IQR) | 36 (32–48) | 43 (35–50) | 40 (31–48) | 0.131 | 40 (33–49) | |
| Hypertension, n (%) | 27/63 (42.8) | 50/101 (49.5) | 36/103 (35.0) | 0.109 | 113/267 (42.3, 36.5–48.4) | |
| Diabetes, n (%) | 13/63 (20.6) | 21/101 (20.8) | 17/103 (16.5) | 0.693 | 51/267 (19.1, 14.8–24.3) | |
| HIV, n (%) | 13/63 (20.6) | 30/101 (29.7) | 33/103 (32.0) | 0.270 | 76/267 (28.5, 23.4–34.2) | |
| Serum creatinine (µmol/L), median (IQR) | 807 (529–1050) | 995.5 (708–1050) | 883 (650–1184) | 0.033 | 890 (670–1210) | |
| Reason for exclusion from KRT programme | ||||||
| Concomitant organ dysfunction, n (%) | 25/44 (56.8) | 45/73 (61.6) | 39/68 (57.4) | 0.830 | 109/185 (58.9; 51.6–65.8) | Reference |
| Cardiac disease, n (%) | 9/44 (20.4) | 16/73 (21.9) | 22/68 (32.4) | 0.250 | 47/185 (25.4;19.6–32.2) | Reference |
| Vascular disease, n (%) | 7/44 (20.4) | 8/73 (23.3) | 12/68 (16.2) | 0.511 | 27/185 (14.6; 10.2–20.5) | 0.009 |
| Pulmonary hypertension, n (%) | 9/44 (20.4) | 17/73 (23.3) | 11/68 (16.2) | 0.571 | 37/185 (20.0; 14.8–26.4) | 0.215 |
| Lung disease, n (%) | 1/44 (2.3) | 5/73 (6.8) | 2/68 (2.9) | 0.467 | 8/185 (4.3; 2.2–8.4) | < 0.001 |
| Noncompliance, n (%) | 4/44 (9.1) | 2/73 (2.7) | 4/68 (5.9) | 0.286 | 10/185 (5.4; 2.9–9.8) | < 0.001 |
| Psychosocial, n (%) | 2/44 (4.6) | 2/73 (2.7) | 4/68 (5.9) | 0.660 | 8/185 (4.3; 2.2–8.4) | < 0.001 |
| Substance abuse, n (%) | 2/44 (4.6) | 4/73 (5.5) | 1/68 (1.5) | 0.483 | 7/185 (3.8; 1.8–7.8) | < 0.001 |
| Diabetes and age ≥ 50 years, n (%) | 3/44 (6.8) | 9/73 (12.3) | 2/68 (2.9) | 0.124 | 14/185 (7.6; 4.5–12.4) | < 0.001 |
| Uncontrolled HIVc, n (%) | 3/44 (6.8) | 9/73 (12.3) | 9/68 (13.2) | 0.610 | 21/185 (11.4; 7.5–16.8) | < 0.001 |
| Age ≥ 60 years, n (%) | 4/44 (9.1) | 7/73 (9.6) | 6/68 (8.8) | 1.000 | 17/185 (9.2; 5.8–14.3) | < 0.001 |
| BMI ≥ 35 kg/m2, n (%) | 3/44 (6.8) | 3/73 (4.1) | 7/68 (10.3) | 0.357 | 13/185 (7.0; 4.1–11.8) | < 0.001 |
| Other, n (%) | 2/44 (4.6) | 3/73 (4.1) | 4/68 (5.9) | 0.910 | 9/185 (4.9; 2.5–9.1) | < 0.001 |
BMI body mass index; CI confidence interval; ESKD end-stage kidney disease; HIV human immunodeficiency virus; IQR interquartile range; pmp per-million-population; KRT kidney replacement therapy
aComparison of 2016 and 2017 incidence rates
bComparison of 2016 and 2018 incidence rates
cUncontrolled HIV refers to unsuppressed viral load